Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis ...

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, ...

US pharma giant Pfizer today released positive top line results from the final prespecified overall survival (OS) analysis of ...

“These overall survival results indicate potentially practice-changing efficacy for TALZENNA in combination with XTANDI for men with metastatic castration-resistant prostate cancer,” said ...

NEW YORK, October 10, 2024--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA® (talazoparib ...

Thursday reported positive topline results from the Phase 3 TALAPRO-2 study of Talzenna in combination with Xtandi ...

In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...

Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of ...